Moderna’s mRNA vaccine manufacturing facility

Australia’s first large-scale mRNA vaccine manufacturing facility

Linesight, has been engaged by Moderna, a biotechnology company, specialising in mRNA vaccines and therapeutics, to deliver Project Management and Project Controls services for its new production facility in Melbourne, Australia.

Supporting Australia’s Pandemic Readiness Capabilities

The project, now under construction at the Monash Technology Precinct in Melbourne, is Australia’s first large-scale mRNA vaccine manufacturing facility and contributes to a world-class mRNA ecosystem being established across the country. The facility is expected to be capable of producing 100 million vaccine doses annually, from COVID-19 booster shots to vaccines for other respiratory viruses.

More than the vast impact on healthcare for Australians, the socio-economic impact of the agreement with the Australian government includes construction to support up to 500 jobs and highly skilled medical manufacturing and research roles once the facility is operational. It will also further enhance medical research and development in the country as well as clinical trials and global supply chain access.

The facility will ensure that Australia can respond more effectively and efficiently to future pandemics.

Navigating the construction market

The Linesight team comprises of subject matter experts in Life Sciences, with strong technical background and local construction market knowledge, which support more informed decisions for a successful project delivery to help the client navigate the complexities of the construction space.

As a multinational construction consultancy, we leverage our unparalleled access to local, regional and global experts and integrate best practices into the project. Linesight has carried out research and studies in advance of the project and facilitated knowledge sharing in relation to procurement strategies, contracting methodologies, material and equipment lead times, and local/state requirements, among others. The team constantly liaises with the client as well as other stakeholders including design consultants and contractors, to ensure transparency across each stage of the project.

“The safe and timely delivery of critical vaccines to market continues to contribute hugely to protecting frontline health care and social workers as well as populations at large. Our collaboration with Moderna on this significant build project will have a positive impact on healthcare developments in Australia and we are proud to be working with them. The scope and scale of this project represents the expansion of Linesight’s business in the Life Sciences space locally, and we are exceptionally excited to be part of this journey,”

said Natalie Mills, Director, Linesight Australia.